GU Malignancy Recap from 2025 ASCO
GU Malignancy Recap from 2025 ASCO

Tian Zhang, MD, MHS

Breakthroughs in Bladder, Prostate, and Kidney Cancer: What Oncologists Need to Know From ASCO 2025
Breakthroughs in Bladder, Prostate, and Kidney Cancer: What Oncologists Need to Know From ASCO 2025

Saad Atiq, MD

Durvalumab Enters the Perioperative Landscape in Muscle-Invasive Bladder Cancer: Reflections from the NIAGARA Trial and ASCO 2025 Updates
Durvalumab Enters the Perioperative Landscape in Muscle-Invasive Bladder Cancer: Reflections from the NIAGARA Trial and ASCO 2025 Updates

Charbel Matar, MD

New Questions in Muscle-Invasive Bladder Cancer After the NIAGARA Trial
New Questions in Muscle-Invasive Bladder Cancer After the NIAGARA Trial

Albert Jang, MD, Michael Serzan, MD

Highlights From the AMPLITUDE Study at ASCO 2025
Highlights From the AMPLITUDE Study at ASCO 2025

Albert Jang, MD, Michael Serzan, MD

Updated CheckMate 214 Results Support Ipi-Nivo for Favorable-Risk Kidney Cancer
Updated CheckMate 214 Results Support Ipi-Nivo for Favorable-Risk Kidney Cancer

Albert Jang, MD, Michael Serzan, MD

Second-Line Treatment Sequencing in Metastatic RCC
Second-Line Treatment Sequencing in Metastatic RCC

Enrique Grande, MD, PhD, MSC, Karan Jatwani, MD

NIAGARA Trial: A New Standard of Care in MIBC
NIAGARA Trial: A New Standard of Care in MIBC

Petros Grivas, MD, PhD, Michael Serzan, MD

The Future of Sacituzumab Govitecan in Metastatic Urothelial Cancer
The Future of Sacituzumab Govitecan in Metastatic Urothelial Cancer

Michael Serzan, MD, Petros Grivas, MD, PhD